Navigation Links
Sequenom Announces Final Approval of Settlement in Class Action Securities Lawsuit
Date:5/5/2010

SAN DIEGO, May 5 /PRNewswire-FirstCall/ -- Sequenom, Inc. (Nasdaq: SQNM) today announced that on May 3, 2010, following a hearing, the U.S. District Court for the Southern District of California entered an order approving the stipulation of settlement reached in the class action securities lawsuits consolidated under the caption In re Sequenom, Inc. Securities Litigation, Master File No. 3:09-cv-00921 LAB-WMC.  A copy of the stipulation of settlement is attached as an exhibit to Sequenom's current report on Form 8-K filed on January 15, 2010.

(Logo:  http://www.newscom.com/cgi-bin/prnh/20040415/SQNMLOGO)

About Sequenom

Sequenom, Inc. (NASDAQ: SQNM) is a life sciences company committed to improving healthcare through revolutionary genetic analysis solutions. Sequenom develops innovative technology, products and diagnostic tests that target and serve discovery & clinical research, and molecular diagnostics markets. The company was founded in 1994 and is headquartered in San Diego, California. Sequenom maintains a Web site at http://www.sequenom.com to which Sequenom regularly posts copies of its press releases as well as additional information about Sequenom. Interested persons can subscribe on the Sequenom Web site to email alerts or RSS feeds that are sent automatically when Sequenom issues press releases, files its reports with the Securities and Exchange Commission or posts certain other information to the Web site.

Sequenom® is a trademark of Sequenom, Inc.


'/>"/>
SOURCE Sequenom, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. University of Michigan Study Shows SEQUENOMs MassARRAY Technology Identifies HPV Infections Missed by Standard Hybridization Test
2. Sequenom Announces Paul Maier to Become Interim Chief Financial Officer
3. Sequenom Announces Addition to Clinical Advisory Board
4. Sequenom Announces Settlement Agreement In Shareholder Class Action Lawsuit
5. Sequenom Announces Launch of SensiGene Fetal(XY) (Fetal Sex Determination) Test
6. Sequenom Reports 2009 Fourth Quarter and Full Year Financial Results
7. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
8. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
9. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
10. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
11. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... Mar 29, 2017 Research and Markets has ... Forecast to 2023" report to their offering. ... The ablation device global market ... $20,995.5 million by 2023. Ablation is the minimally ... purposes, from cancerous or diseased tissue removal, to the removal of ...
(Date:3/29/2017)... , March 29, 2017   Dynatronics ... today the appointment of Cynthia L. McHenry ... will be responsible for leading Dynatronics manufacturing, distribution, ... will report to Dynatronics, CEO Kelvyn H. ... concludes an extensive search process conducted by the ...
(Date:3/29/2017)... FinancialBuzz.com News Commentary  ... Data published in a research report by Grand View Research, ... of USD 55.8 billion by 2025. The projection takes into consideration the ... and a more open approach towards cannabis products around the world. In ... , North Dakota , Ohio , ...
Breaking Medicine Technology:
(Date:3/29/2017)... ... March 29, 2017 , ... ... without a referral to new patients from Burnaby, BC. Patients in need of ... mouth reconstruction services, can see the esteemed team at Wall Centre Dental. Drs. ...
(Date:3/29/2017)... ... 2017 , ... Patients interested in receiving quick and effective ... Cameron, with or without a referral. The FASTBRACES system is valued for its ... patient’s case, treatment with the FASTBRACES system could be completed in 120 days ...
(Date:3/29/2017)... ... March 29, 2017 , ... ... continues developing an ANSI-approved, consensus-based American National Standard for Good Manufacturing Practices ... the first ANSI-approved GMP standard for dietary supplements this spring, is hiring ...
(Date:3/29/2017)... ... 29, 2017 , ... Altima Technologies, Inc., the maker of ... center assets and audio-video devices has recently updated its Visio Stencils library with ... and download shapes and stencils from http://www.VisioStencils.com. , New devices were ...
(Date:3/29/2017)... PITTSBURGH, PA (PRWEB) , ... March 29, 2017 ... ... and hassles associated with wearing oral braces. "The rubber bands used in conjunction ... he said, "so I decided to design a way to prevent this problem." ...
Breaking Medicine News(10 mins):